Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 291 Carcinoma, Non-Small-Cell Lung 206 Prostatic Neoplasms 158 Lung Neoplasms 93 Stomach Neoplasms 69 Neoplasms 69 Head and Neck Neoplasms 60 Squamous Cell Carcinoma of Head and Neck 56 Neoplasm Metastasis 50 Esophageal Neoplasms 49 Ovarian Neoplasms 39 Pancreatic Neoplasms 26 Sarcoma 23 Carcinoma, Ovarian Epithelial 20 Urinary Bladder Neoplasms 19 Unspecified Adult Solid Tumor, Protocol Specific 19 Breast Neoplasms, Male 17 Adenocarcinoma Of Esophagus 17 Parkinson Disease 4, Autosomal Dominant Lewy Body 16 Esophageal Squamous Cell Carcinoma 16 Adenocarcinoma of Lung 16 Fallopian Tube Neoplasms 14 Carcinoma, Squamous Cell 14 Adenocarcinoma 12 Melanoma 11 Inflammatory Breast Neoplasms 11 Uterine Cervical Neoplasms 9 Triple Negative Breast Neoplasms 9 Salivary Gland Neoplasms 8 Endometrial Neoplasms 8

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Malignant Disease × Docetaxel × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡